Laurent Meijer, PhD, University of Paris 1983
Affiliations: | Cell Cycle Group | CNRS, Station Biologique de Roscoff, Roscoff, Bretagne, France |
Area:
http://www.biomedexperts.com/Profile.bme/924584/Laurent_MeijerWebsite:
http://www.esi-topics.com/erf/2004/august04-LaurentMeijer.htmlGoogle:
"Laurent Meijer"Bio:
http://www.manros-therapeutics.com/en/about/people.php
http://www.antimal.eu/partners/LaurentMeijer.htm
http://en.scientificcommons.org/laurent_meijer
http://www.mitologics.com/index.php?menu=8
Mean distance: 15.62 (cluster 28) | S | N | B | C | P |
Parents
Sign in to add mentor| David Epel | post-doc | 1978-1978 | Hopkins Marine Station, Stanford University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Deau E, Lindberg MF, Miege F, et al. (2023) Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B. Journal of Medicinal Chemistry |
| Meijer L, Dube F, Guerrier P. (2023) Trifluoperazine-Sensitive Step during Sea Urchin, Echiuroid and Pelecypod Egg Activation: (trifluoperazine/calmodulin/calcium/maturation/fertilization). Development, Growth & Differentiation. 25: 469-475 |
| Lindberg MF, Deau E, Arfwedson J, et al. (2023) Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. Journal of Medicinal Chemistry |
| Sunkari YK, Meijer L, Flajolet M. (2022) The protein kinase CK1: Inhibition, activation, and possible allosteric modulation. Frontiers in Molecular Biosciences. 9: 916232 |
| Tahtouh T, Durieu E, Villiers B, et al. (2021) Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors. Journal of Medicinal Chemistry |
| Bourahla K, Guihéneuf S, Limanton E, et al. (2021) Design and Microwave Synthesis of New (5) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5) 2-Amino-5-arylidene-1,3-thiazol-4(5)-one as New Inhibitors of Protein Kinase DYRK1A. Pharmaceuticals (Basel, Switzerland). 14 |
| Lindberg MF, Meijer L. (2021) Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. International Journal of Molecular Sciences. 22 |
| Loidreau Y, Dubouilh-Benard C, Nourrisson MR, et al. (2020) Exploring Kinase Inhibition Properties of 9-pyrimido[5,4-]- and [4,5-]indol-4-amine Derivatives. Pharmaceuticals (Basel, Switzerland). 13 |
| Fruit C, Couly F, Bhansali R, et al. (2019) Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-]quinazolin-9(8)-one, a Promising Inhibitor of DYRK1A. Pharmaceuticals (Basel, Switzerland). 12 |
| Lechner C, Flaßhoff M, Falke H, et al. (2019) []-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors. Molecules (Basel, Switzerland). 24 |